The use of single sample clearance estimates to probe hepatic drug metabolism: handprinting the influence of cigarette smoking on human hepatic drug metabolism

References

• Bachmann K., Shapiro R., Fulton R., Carroll F., Sullivan T. Smoking and warfarin disposition. Clinical Pharmacology and Therapeutics 1979; 25: 309–315
   PubMed Web of Science ®Google Scholar
• Bachmann K., Schwartz J., Forney R., Jr., Sheman G., Jauregui L. Selectivity of cholestyramine treatment on hepatic mixed function oxidase activity. Pharmacology 1984; 29: 128–141
   PubMed Web of Science ®Google Scholar
• Bachmann K., Schwartz J., Forney R., Jr., Jauregui L. Theophylline kinetics: dose dependency and single sample prediction of clearance. Pharmacology 1985; 30: 136–144
   PubMed Web of Science ®Google Scholar
• Bachmann K., Schwartz J., Forney R., Jr., Jauregui L. Phenytoin as a probe of drug metabolism: predicting clearance with a salivary sample. Pharmacology 1985; 30: 145–152
   PubMed Web of Science ®Google Scholar
• Bachmann K., Schwartz J., Sullivan T., Jauregui L. Single sample estimate of ethosuximide clearance. International Journal of Clinical Pharmacology, Therapy, and Toxicology 1986; 24: 546–550
   PubMedGoogle Scholar
• Bachmann K., Schwartz J., Jauregui L. The suitability of carbamazepine as a single-sample probe of human mixed function oxidase activity. Xenobiotica 1989; 19: 711–719
   PubMed Web of Science ®Google Scholar
• Bachmann K. The use of single sample clearance estimates to probe hepatic drug metabolism in rats. IV. A model for possible application to phenotyping xenobiotic-influences on human drug metabolism. Xenobiotica 1989; 19: 1449–1459
   PubMed Web of Science ®Google Scholar
• Baille T., Rettenmeir A. W. Valproate: biotransformation. Antiepileptic Drugs, R. H. Levy, F. Dreifuss, R. Mattson, B. Meldrum, J. K. Penry. Raven Press, New York 1990
   Google Scholar
• Benetello P, Furlanut M., Pasqui L., Perlotto N., Testa G. Absence of effect of cigarette smoking on serum concentrations of some anticonvulsants in epileptic patients. Clinical Pharmacokinetics 1987; 12: 302–304
   PubMed Web of Science ®Google Scholar
• Burke M., Wolf R. Substrates and inhibitors as probes of individual forms of drug metabolizing systems,. Drug Metabolism—from Molecules to Man, D. Benford, J. Bridges, G. Gibson. Taylor & Francis, London 1987; 219–243
   Google Scholar
• Campbell M., Spielberg S., Kalow W. A urinary metabolite ratio that reflects systemic caffeine clearance. Clinical Pharmacology and Therapeutics 1987; 42: 157–165
   PubMed Web of Science ®Google Scholar
• Dandliker W., Kelly R. Fluorescence polarization immunoassay: theory and experimental method. Immunochemistry 1973; 10: 219–227
   PubMedGoogle Scholar
• Daver P., Leemann T., Striberni R. Dextromethorphan O-demethylation in liver microsomes as a prototype reaction to monitor cytochrome P-450 DB1 activity. Clinical Pharmacology and Therapeutics 1989; 45: 34–40
   PubMed Web of Science ®Google Scholar
• Dossing M., Poulsen H., Andreasen P. B., Tygstrup N. A simple method for determination of antipyrine clearance. Clinical Pharmacology and Therapeutics 1982; 32: 392–396
   PubMed Web of Science ®Google Scholar
• Edwards D., Axelson J., Visco J., van Every S., Slaughter R., Lalka D. Lack of effect of smoking on the metabolism and pharmacokinetics of quinidine in patients. British Journal of Clinical Pharmacology 1987; 23: 351–354
   PubMed Web of Science ®Google Scholar
• Eichelbaum M., Tomson T., Tybring G., Bertilsson L. Carbamazepine metabolism in man: induction and pharmacogenetic aspects. Clinical Pharmacokinetics 1985; 10: 80–90
   PubMed Web of Science ®Google Scholar
• Halpert J. Multiplicity of steroid-inducible cytochromes P-450 in rat liver microsomes. Archives of Biochemistry and Biophysics 1988; 263: 59–68
   PubMed Web of Science ®Google Scholar
• Hepner G., Vesell E. Assessment of aminopyrine metabolism in man by breath analysis after oral administration of [14C]-aminopyrine. New England Journal of Medicine 1974; 291: 1384–1388
   PubMed Web of Science ®Google Scholar
• Hvidberg E. Ethnic differences in phenytoin kinetics. Ethnic Differences in Reactions to Drugs and Xenobiotics, W. Kalow, H. Goedde, D. Argarwal. Alan Liss, New York 1986; 279–287
   Google Scholar
• Inaba T., Tang B., Endrenyi L., Kalow W. Amobarbital—a probe of hepatic oxidation in man. Clinical Pharmacology and Therapeutics 1976; 20: 439–444
   PubMed Web of Science ®Google Scholar
• Jolley M. Fluorescence polarization immunoassay for the determination of therapeutic drug levels in human plasma. Journal of Analytical Toxicology 1981; 5: 236–240
   PubMed Web of Science ®Google Scholar
• Jusko W. Role of tobacco smoking in pharmacokinetics. Journal of Pharmacokinetics and Biopharmaceutics 1978; 6: 7–39
   PubMedGoogle Scholar
• Kalow W. Genetic variation in the human hepatic cytochrome P-450 system. European Journal of Clinical Pharmacology 1987; 31: 633–641
   PubMed Web of Science ®Google Scholar
• Muller-Enoch D., Guengerich F. P. Oxidation of quinidine by human liver cytochrome P-450. Drug Metabolism—from Molecules to Man, D. Benford, J. Bridges, G. Gibson. Taylor & Francis, London 1987; 115–120
   Google Scholar
• Nebert D., Gonzalez F. P-450 genes: structure, evolution, and regulation. Annual Reviews of Biochemistry 1987; 56: 945–993
   PubMed Web of Science ®Google Scholar
• Ochs H., Greenblatt D., Knuchel M. Kinetics of diazepam, midazolam, and lorazepam in cigarette smokers,. Chest 1985; 87: 223–226
   PubMed Web of Science ®Google Scholar
• Park B. In vivo probes for drug metabolizing enzymes, Drug Metabolism—from Molecules to Man, D. Benford, J. Bridges, G. Gibson. Taylor & Francis, London 1987; 285–296
   Google Scholar
• Rose J., Barron S., Jusko W. Phenytoin disposition in smokers and non-smokers. International Journal of Clinical Pharmacology 1978; 16: 547–550
   Google Scholar
• Sheiner L., Beal S. Some suggestions for measuring predictive performance. Journal of Pharmacokinetics and Biopharmaceutics 1981; 9: 503–512
   PubMedGoogle Scholar
• Shumaker R. PKCALC: A BASIC interactive computer program for statistical and pharmacokinetic analysis of data. Drug Metabolism Reviews, 17: 331–348
   PubMed Web of Science ®Google Scholar
• Sloan T., Idle J., Smith R. Influence of D/D alleles regulating debrisoquine oxidation or phenytoin hydroxylation. Clinical Pharmacology and Therapeutics 1981; 29: 493–497
   PubMed Web of Science ®Google Scholar
• Vesell E. The antipyrine test in clinical pharmacology: conceptions and misconceptions. Clinical Pharmacology and Therapeutics 1979; 26: 275–286
   PubMed Web of Science ®Google Scholar
• Vestal R., Cusack B., Mercer G., Dawson G., Park B. K. Aging and drug interactions. I. Effect of cimetidine and smoking on the oxidation of theophylline and cortisol in healthy men. Journal of Pharmacology and Experimental Therapeutics 1987; 241: 488–500
   PubMed Web of Science ®Google Scholar
• Vestal R., Norris A., Tobin J., Cohen B., Shock N., Andres R. Antipyrine metabolism in man: influence of age, alcohol, caffeine, and smoking. Clinical Pharmacology and Therapeutics 1975; 18: 425–432
   PubMed Web of Science ®Google Scholar